The Trump administration’s federal cannabis policy has taken a dramatic turn. President Trump moved marijuana from Schedule I to Schedule III under the Controlled Substances Act, skipping legally required procedures to do it. The decision builds on an executive action from December 2024. Medical experts, legal scholars, and public health advocates say it puts political convenience ahead of scientific rigour.

The administration pushed this federal cannabis policy through executive order rather than following the structured review process involving the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA). That shortcut raises serious questions about legality and intent.

Federal Cannabis Policy: What the Executive Orders Actually Change

Two overlapping executive actions drive this controversy. The first told federal agencies to reconsider marijuana’s classification under the Controlled Substances Act. The second pushed toward a rescheduling outcome without resolving the underlying scientific questions.

That ambiguity matters. One order suggests a review process. The other implies a predetermined conclusion. Critics say policymakers shaped the outcome before the evidence had run its course.

The administration also handed regulatory authority over medical marijuana research licensing under Schedule III to individual state programmes. Legal experts say the executive branch does not hold that authority. Opponents call it backdoor legalisation, and they argue it grants federal recognition to state-run schemes that have long harmed families across the country.

The Medical Standard This Federal Cannabis Policy Ignores

Schedule III substances must carry accepted medical use under federal law. Doctors prescribe them. Pharmacies dispense them through tightly regulated supply chains. The FDA approves them. Marijuana satisfies none of those conditions.

No plant-based marijuana product holds FDA approval as a medicine. Potency varies widely. Standardised dosing does not exist. The current federal cannabis policy asks the public to accept a medical label for a substance that has not completed the clinical trials any comparable drug must pass.

That gap creates real problems. If marijuana becomes Schedule III, pharmacies face an immediate question: where do they source it? The pharmaceutical supply chain requires standardised manufacturing, quality assurance, and regulatory oversight. Dispensaries, often referred to more accurately as pot shops, provide none of that. They do not meet pharmacy regulations. They do not connect to the controlled substance tracking systems healthcare providers use nationwide.

“Medical” in Name Only: How the Cannabis Drug Policy Reality Falls Short

State-level medical marijuana programmes have stretched the word “medical” well past its clinical meaning. In several states, a brief online consultation, a self-reported condition, and a payment are all someone needs to qualify. No standardised clinical assessment takes place. No follow-up care follows.

One coalition member reported obtaining three “medical marijuana” recommendations without once seeing a doctor in person. A receptionist handed over pre-signed forms after collecting a payment. Another qualified after a 45-second video call during which he mentioned feeling anxious while driving children to football practice. That is the quality of medical care this cannabis drug policy legitimises.

Former US Surgeon General Jerome Adams said during his tenure that the term “medical marijuana” misleads the public. He stressed that the evidence does not support broad medical claims. Dr Bertha Madras, a neuropsychopharmacologist and former deputy director of the Office of National Drug Control Policy, points to further problems: inconsistent potency, no standardised dosing, thin clinical trial data, and documented risks including cognitive impairment, addiction, and psychiatric harm. Research linking marijuana use to violent crime also continues to grow.

These concerns are not fringe positions. They reflect mainstream thinking across medicine and science. This federal cannabis policy does nothing to address them.

A Billion-Dollar Windfall for Industry, Not Patients

The financial stakes are enormous. Under Section 280E of the Internal Revenue Code, marijuana businesses currently cannot deduct standard operating expenses from federal taxes because the substance sits in Schedule I or II. Moving marijuana to Schedule III removes that restriction. The cannabis industry stands to gain billions in tax relief overnight.

Gallup and YouGov polling shows public support for marijuana legalisation has fallen to historic lows. In Massachusetts, tens of thousands of voters signed petitions demanding a public vote on repealing legal cannabis sales. Communities across the country are rethinking what commercialisation actually costs them.

Senators Pete Ricketts and James Lankford, joined by Representative Jodey Arrington, introduced the No Deductions for Marijuana Businesses Act to block those tax benefits if rescheduling moves forward. The bill signals that not everyone in Washington views this federal cannabis policy as settled.

Legal Challenges Already Under Way Against This Cannabis Drug Policy

This decision faces serious opposition. Americans Against Legalizing Marijuana condemned the executive action, calling it a politically expedient shortcut that bypasses the scientific and regulatory processes built to protect public health. Smart Approaches to Marijuana retained Torridon Law, the firm of former US Attorney General Bill Barr, to sue the administration over the rule.

The legal argument is clear. Drug scheduling under the Controlled Substances Act follows a structured process. Executive preference is not part of that process. By bypassing it, the administration has opened the door to a legal dispute that could redefine how America makes drug policy for years to come.

What Evidence-Based Cannabis Drug Policy Actually Looks Like

A genuine path to medical recognition exists for marijuana. It runs through controlled clinical trials, FDA approval, standardised production, and accountable distribution. Every other drug travels that road. There is no credible reason to exempt this one.

Skipping that process does not make marijuana a medicine. It redefines the word to serve a politically convenient outcome. Worse, it sends a misleading signal to the public, especially young people, that the substance is safe or medically legitimate.

Policy driven by industry profits and executive shortcuts, rather than evidence, is not progress. It undermines the very framework that has long kept America’s drug approval system honest.

Source: dbrecoveryresources